1102888-26-5 Usage
Description
(S)-2-(4-fluorobenzamido)-3-hydroxypropanoic acid is a chemical compound with the molecular formula C10H10FNO4. It is a derivative of the amino acid phenylalanine, containing a 4-fluorobenzoyl group and a 3-hydroxypropanoic acid group. (S)-2-(4-fluorobenzamido)-3-hydroxypropanoic acid has potential pharmaceutical applications due to its ability to interact with biological systems. Specifically, it may exhibit properties that make it useful for the treatment of certain diseases or conditions. Its molecular structure and properties make it a subject of interest for further research and potential drug development.
Uses
Used in Pharmaceutical Industry:
(S)-2-(4-fluorobenzamido)-3-hydroxypropanoic acid is used as a potential therapeutic agent for the treatment of certain diseases or conditions. Its unique molecular structure allows it to interact with biological systems, making it a promising candidate for drug development.
Used in Research and Development:
(S)-2-(4-fluorobenzamido)-3-hydroxypropanoic acid is used as a subject of interest for further research in the field of pharmaceuticals. Its properties and interactions with biological systems provide valuable insights for the development of new drugs and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 1102888-26-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,0,2,8,8 and 8 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1102888-26:
(9*1)+(8*1)+(7*0)+(6*2)+(5*8)+(4*8)+(3*8)+(2*2)+(1*6)=135
135 % 10 = 5
So 1102888-26-5 is a valid CAS Registry Number.
1102888-26-5Relevant articles and documents
KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 0301-0302, (2016/09/26)
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
